ReviewFrontiers in endocrinology2020
Androgen Receptor in Breast Cancer: From Bench to Bedside.
Review in Frontiers in endocrinology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 2 syntheses or guidelines pooled it, 46 citations in OpenAlex.
- Relevance of the 21-gene expression assay in male breast cancer: A systematic review and meta-analysis.Breast (Edinburgh, Scotland) · 2022Pooled it
- Global Trends in Research of Androgen Receptor Associated With Breast Cancer From 2011 to 2020: A Scientometric Analysis.Frontiers in endocrinology · 2022Pooled it
- Abiraterone Acetate in Patients With Castration-Resistant, Androgen Receptor-Expressing Salivary Gland Cancer: A Phase II Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2021Trial
- Integrative transcriptomic analysis reveals novel targets for personalized medicine across seven metastatic breast cancer subtypes.Scientific reports · 2026Article
- Emerging Protein Targets in Triple-Negative Breast Cancer: Beyond Conventional Therapy.Cancers · 2026Review
- The Role of Androgen Receptor and Antiandrogen Therapy in Breast Cancer: A Scoping Review.Current oncology (Toronto, Ont.) · 2026Review
- The Impact of Androgen Receptor Expression on Neoadjuvant Therapy in HER2-Positive Breast Cancer.Breast cancer (Dove Medical Press) · 2026Article
- Impact of androgen receptor on triple negative breast cancer: a systematic review and meta-analytic study.BMJ public health · 2026Article
- Development and validation of an interpretable ensemble model for predicting androgen receptor status in triple-negative breast cancer: a multi-center study.Frontiers in oncology · 2026Article
- Article
- Dual Functions of Androgen Receptor Overexpression in Triple-Negative Breast Cancer: A Complex Prognostic Marker.Bioengineering (Basel, Switzerland) · 2025Article
- Prognostic and Clinical Significance of PD-L1, EGFR and Androgen Receptor (AR) Expression in Triple-Negative Breast Cancer (TNBC) Patients.Life (Basel, Switzerland) · 2024Article
- Determination of the androgen receptor status of disseminated tumor cells in primary breast cancer patients.Archives of gynecology and obstetrics · 2024Article
- Sex-Hormone-Binding Globulin Gene Polymorphisms and Breast Cancer Risk in Caucasian Women of Russia.International journal of molecular sciences · 2024Article
- Androgen and Estrogen β Receptor Expression Enhances Efficacy of Antihormonal Treatments in Triple-Negative Breast Cancer Cell Lines.International journal of molecular sciences · 2024Article
- Clinicopathological Factors Associated with Oncotype DX Risk Group in Patients with ER+/HER2- Breast Cancer.Cancers · 2023Article
- Correlation between androgen receptor expression and pathological response rate in pre-operative HER2-positive breast cancer patients.Journal of cancer research and clinical oncology · 2023Article
- Revisiting the Syndecans: Master Signaling Regulators with Prognostic and Targetable Therapeutic Values in Breast Carcinoma.Cancers · 2023Review
- Correlation analysis between androgen receptor and the clinicopathological features and prognosis of mammary Paget's disease.Journal of cancer research and clinical oncology · 2023Article
- Cheminformatic Analysis and Machine Learning Modeling to Investigate Androgen Receptor Antagonists to Combat Prostate Cancer.ACS omega · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer (BC) is one of the most common malignancies and the leading cause of cancer-related mortality in women. Androgen receptor (AR) is frequently expressed in diverse BC subtypes. Accumulating evidence has revealed that AR might be a predictive or prognostic factor and a drug target in BC. AR expression and AR pathways differ in various BC subtypes, thereby resulting in controversial inferences on the predictive and prognostic value of AR. Herein, we summarized the roles of AR in different BC subtypes and AR-targeting therapies based on preclinical and clinical studies. Moreover, we highlighted the possible efficacy of a combination therapy via exploiting the AR-related mechanisms and the research on therapeutic resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.